Edition:
India

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

1.57USD
16 Oct 2019
Change (% chg)

$0.04 (+2.61%)
Prev Close
$1.53
Open
$1.52
Day's High
$1.60
Day's Low
$1.52
Volume
3,713
Avg. Vol
35,160
52-wk High
$4.61
52-wk Low
$1.07

Latest Key Developments (Source: Significant Developments)

Achieve Reports Qtrly Loss Per Share $0.50
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2019 AND PROVIDES CYTISINICLINE CLINICAL DEVELOPMENT UPDATE.QTRLY LOSS PER SHARE $0.50.Q2 EARNINGS PER SHARE VIEW $-0.56 -- REFINITIV IBES DATA.  Full Article

Achieve Qtrly Loss Per Share $0.88
Thursday, 16 May 2019 

May 15 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2019 AND PROVIDES CYTISINICLINE CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES INC - QTRLY LOSS PER SHARE $0.88.ACHIEVE LIFE SCIENCES INC - AS OF MARCH 31, 2019, COMPANY'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH WERE $9.7 MILLION.  Full Article

Achieve Life Sciences - QTRLY Loss Per Share $0.71
Thursday, 8 Nov 2018 

Achieve Life Sciences Inc ::ACHIEVE REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2018 AND PROVIDES CYTISINICLINE (CYTISINE) CLINICAL DEVELOPMENT UPDATE.ACHIEVE LIFE SCIENCES - QTRLY LOSS PER SHARE $0.71.  Full Article

Achieve Life Sciences Inc Qtrly Loss Per Share ‍$0.32​
Friday, 2 Mar 2018 

March 1 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE LIFE SCIENCES INC QTRLY LOSS PER SHARE ‍$0.32​.  Full Article

Achieve Announces Prelim Data From Cytisine Phase I/II Clinical Study
Tuesday, 20 Feb 2018 

Feb 20 (Reuters) - Achieve Life Sciences Inc ::ACHIEVE ANNOUNCES PRELIMINARY DATA FROM CYTISINE PHASE I/II MULTI-DOSE, PHARMACOKINETIC AND PHARMACODYNAMICS (PK/PD) CLINICAL STUDY.ACHIEVE LIFE SCIENCES INC - CYTISINE WAS WELL-TOLERATED AND REPORTED ADVERSE EVENTS WERE MOSTLY MILD AND SHORT-LIVED IN STUDY.ACHIEVE LIFE SCIENCES - SUBJECTS WHO DID NOT ACHIEVE ABSTINENCE HAD "SIGNIFICANT REDUCTION" IN NUMBER OF DAILY CIGARETTES SMOKED BY END OF TREATMENT.ACHIEVE LIFE SCIENCES INC - NO ADVERSE EVENTS WERE SEVERE, SERIOUS, OR LED TO WITHDRAWAL FROM STUDY.ACHIEVE LIFE SCIENCES INC - EXPECTS TO INITIATE CYTISINE PHASE 3 DEVELOPMENT PROGRAM IN MID-2018 REQUIRED FOR FDA APPROVAL OF CYTISINE IN U.S..  Full Article

Achieve qtrly loss per share $0.90‍​
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Achieve Life Sciences Inc ::Achieve reports financial results for third quarter 2017.Achieve Life Sciences Inc qtrly loss per share $0.90‍​.  Full Article